CAR T cells manufactured with interleukin-15 are predicted to exhibit an enhanced and more sustained release of effector cytokines, such as IFN-γ and TNF-α, upon antigen stimulation, due to their superior persistence and proliferative capacity compared to T cells manufactured without interleukin-15.